J&J unit enrolls first patient in SMART-AF study

Biosense Webster, a unit of Johnson & Johnson, has reported the enrollment of the first patient in the SMART-AF IDE study, as well as the treatment of the first patient with the new Thermocool Smarttouch contact force sensing catheter and software module in the U.S. SMART-AF expects to enroll up to 164 patients across the country. The study is trying to demonstrate the safety and effectiveness of the Thermocool Smarttouch in the treatment of symptomatic, drug-refractory, paroxysmal atrial fibrillation Biosense Webster release

Suggested Articles

The drug that treats atrial fibrillation, flecainide, has been around since the '80s. Grace Colón, CEO of InCarda, thinks it needs a face-lift.

3M, maker of the ubiquitous Littmann stethoscope brand, has teamed up with Eko to create a new digital version that amplifies sounds and adds AI.

Study data from Medtronic showed more patients reported improvements in their chronic back pain after treatments with the devicemaker’s tiny implant.